source
- FDA advisory panel finds Grail's Galleri multicancer blood test benefits outweigh risksA Food and Drug Administration advisory panel voted 7-2, with one abstention, to conclude that the probable benefits of Grail's Galleri multicancer blood test outweigh its risks. The panel unanimou…
- Roche signs up to $2 billion partnership with Atavistik to develop cardiometabolic drugsRoche announced a partnership with Atavistik Bio, a biotech focused on hematology, to pursue new small-molecule treatments for cardiovascular, renal and metabolic conditions. The agreement provide…